|
|
|
|
| LEADER |
01000naa a22002652c 4500 |
| 001 |
NLM384689019 |
| 003 |
DE-627 |
| 005 |
20250508035335.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
250508s2025 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202413002
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1324.xml
|
| 035 |
|
|
|a (DE-627)NLM384689019
|
| 035 |
|
|
|a (NLM)39988842
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zhang, Liang
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Radioactive Diselenide Bonded Covalent Organic Framework
|
| 264 |
|
1 |
|c 2025
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 24.02.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status Publisher
|
| 520 |
|
|
|a © 2025 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Covalent organic frameworks (COFs) are porous crystals of high potential in biomedical applications. The chemical bonds within COF structures are critical for the overall therapeutic performance. Here, the design and synthesis of radioactive COF are reported by introducing labile diselenide bonds into the structure backbone. This diselenide bonded COF, PorSe-CuPt, constructed from Cu and Pt ion porphyrin units, is capable of bond cleavage upon irradiation, thus releasing the drug molecule, CBL0137, carried in the pores. Concerted with the promotion of X-ray absorption by Pt2⁺ and the enrichment of oxygen by Cu2⁺, robust PANoptosis is achieved as well as improved immunosuppressive tumor microenvironment, thereby drastically enhancing the overall effectiveness of radiotherapy. The integration of diselenide bonds into the COF backbone demonstrates the possible application of clip-off chemistry in the search for highly responsible and compatible biomaterials
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a PANoptosis
|
| 650 |
|
4 |
|a covalent organic frameworks (COFs)
|
| 650 |
|
4 |
|a diselenide bonds
|
| 650 |
|
4 |
|a radiotherapy
|
| 700 |
1 |
|
|a Wang, Shuo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Qi-Chao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Song, An
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Yuan-Yuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Wen-Da
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Meng-Jie
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Li, Hao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Zhi-Jun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Deng, Hexiang
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g (2025) vom: 23. Feb., Seite e2413002
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g year:2025
|g day:23
|g month:02
|g pages:e2413002
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202413002
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|j 2025
|b 23
|c 02
|h e2413002
|